werner erhart |
||||||
|
News for 03-Aug-26 Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General
|
The Best werner erhart websiteAll the werner erhart information you need to know about is right
here. Presented and researched by http://www.mdnewscast.net. We've searched
the information super highway far and wide to provide you with the
best werner erhart site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
werner erhart
A treasure chest of werner erhart information.There is no doubt you and I have a great interest in werner erhart after all that's why you arrived at this web page and it's why I created this werner erhart web site. I'm actually passionate about werner erhart and in time will make the site one of the best resources for information. You can search around for hours looking for good werner erhart sites but as you have no doubt found, many of the sites that rank well in search engines for werner erhart are pretty hopeless. While your visit to my site is a little premature because I'm still working on it, in the not too distant future it will become one of the best sites on the net for werner erhart. I'm aware of the needs of people searching the net for werner erhart information and I plan to create a directory of valuable links to werner erhart sites. Every site I list, such as the examples below will carry recommended reading and I'm sure every visitor will be delighted with what they find. Here's just a small example of the links you will find in the future, I'm sure if you visit the site you will not be disappointed. Right now I'm working on making my werner erhart site bigger and better, it's turning out to be a much largerr task than I expected, but because I am passionate about werner erhart I work with great purpose so it's not really work. I invite you to call back sometime and I'm sure I'll have it completed and maybe you can pass on my url to your friends that have similar werner erhart interests. werner erhart
By buying through our recommend links you can also rest assured your werner erhart will be of the highest quality. How do we know? Because when we're shopping for werner erhart ourselves it's where we go. You might wonder why we're suggesting you click on some outside links rather than stay on our werner erhart site. Well it's because we've only just put this site up and haven't yet got it fully operational. Our aim is to be the best site for werner erhart info on the net, and I'm sure that one day soon we'll achieve it. So please bookmark us and come back soon. Meanwhile please follow one of the links. Drug Offers Hope to Cancer Patients by: ARA Content
(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community. Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer. In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow. In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs. Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer. Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy. Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce. Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005. Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.
|
|||||
|
http://www.medmeet.com/ |
||||||
| Go Meetings Meetings On The Net MD Newscast |